A primer combination, method and kit for detecting fusion genes and / or MET gene skipping mutations in solid tumors
By using a combination of multiple specific primer sets and anchoring linkers in fusion gene detection, the accuracy and efficiency of detecting multiple fusion genes and their chaperone genes at limited sample size and less cost is achieved, solving the existing technology False negative results and low cost efficiency.
Patent Information
- Application Number
- CN202310386337.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-07
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-04-07
AI Technical Summary
Existing fusion gene detection methods cannot effectively identify new fusion gene partners, resulting in false negative results, and are low in cost and efficiency, so they cannot detect and cover multiple clinically meaningful targets with limited sample size and less cost.
Provided is a primer combination for detecting fusion genes and/or MET gene skip read mutations in solid tumors, including a first multi-specific primer set and a second multi-specific primer set, amplified by multiple anchoring and multiplex Nested amplification technology, combined with anchoring joints, improves the specificity and efficiency of detection.
It realizes detection of multiple fusion genes and their partner genes under limited sample size and less cost, improves the accuracy and efficiency of detection, can detect rare fusion types, reduces detection costs, and meets the needs of clinical practice.
Smart Images

Figure CN116377076B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of biotechnology, and in particular to a primer combination, method and kit for detecting fusion genes and / or MET gene skipping mutations in solid tumors. Background Art
[0002] Gene fusion represents an important class of somatic mutations in cancer, and the detection of fusion genes plays an important role in the diagnosis and treatment of cancer. Compared with point mutations, gene fusions better reflect the instability of tumor chromosomes. Gene fusions drive the development of 16.5% of cancer cases and serve as the only driving factor in more than 1% of cases. About 6% of cases carry druggable gene fusions. At present, common fusion detection gene detection methods include: fluorescence in situ hybridization (FISH), reverse transcription polymerase chain reaction (RT-PCR), immunohistochemistry (IHC), next-generation sequencing technology (NGS), etc. Existing fusion gene detection methods usually only identify the presence of a single fusion gene, which is expensive and inefficient. In addition, these methods cannot identify new fusion gene partners, which is also the main reason for false negative results. By detecting targets with clinical therapeutic significance, especially providing detection results of multiple targets, more support can be provided for the follow-up treatment of patients.
[0003] Therefore, it is necessary to provide a solid tumor fusion gene method, primers and kit that can detect as many clinically significant fusion targets as possible with limited sample size and low cost. Summary of the invention
[0004] According to one aspect of the present application, a primer combination for detecting fusion genes and / or MET gene skipping mutations in solid tumors is provided, the primer combination comprising: a first multiplex specific primer set comprising a nucleotide sequence as shown in SEQ ID NO.1-54, the first multiplex specific primer set being used for multiplex anchored amplification; and a second multiplex specific primer set comprising a nucleotide sequence as shown in SEQ ID NO.56-109, the second multiplex specific primer set being used for multiplex nested amplification.
[0005] According to another aspect of the present application, a kit for detecting fusion genes and / or MET gene skipping mutations in solid tumors is provided, characterized in that the kit comprises a first multiplex specific primer set, a second multiplex specific primer set and an anchoring linker, the first multiplex specific primer set comprises the nucleotide sequence shown in SEQ ID NO.1-54, and the first multiplex specific primer set is used for multiplex anchoring amplification; the second multiplex specific primer set comprises the nucleotide sequence shown in SEQ ID NO.56-109, and the second multiplex specific primer set is used for multiplex nested amplification; and the anchoring linker comprises the nucleotide sequences shown in SEQ ID NO.111 and SEQ ID NO.112.
[0006] According to another aspect of the present application, a method for detecting solid tumor fusion genes and / or MET gene skipping mutations is provided, the method comprising the following steps: adding RNA shearing solution to a total RNA sample, oscillating and mixing, centrifuging, and running a shearing program to obtain an RNA shearing product; adding a reverse transcription cDNA strand reagent to the RNA shearing product, oscillating and mixing, centrifuging, and running a cDNA strand synthesis program to reverse transcribe to obtain a cDNA strand product; adding a reverse transcription cDNA strand and an end repair plus A reagent to the cDNA strand product, oscillating and mixing, centrifuging, running a cDNA strand synthesis and end repair plus A program, reverse transcribing the cDNA strand and simultaneously performing end repair plus A to obtain a cDNA strand product; connecting the strand cDNA product to an anchor linker, purifying, and obtaining a purified pre-library connected to the anchor linker; connecting the pre-library, the first multiple specific primer set as shown in SEQ ID NO.1-54, and the first multiple specific primer set as shown in SEQ ID NO. The first universal primer shown in NO.55 is added to the PCR reaction system, PCR amplification is performed to obtain multiple anchored amplification products and then purified; and the purified multiple anchored amplification products, the second multiple specific primer set shown in SEQID NO.56-109 and the second universal primer shown in SEQ ID NO.110 are added to the PCR reaction system, PCR amplification is performed to obtain multiple nested amplification products and then purified to obtain a DNA library.
[0007] According to another aspect of the present application, a primer combination for detecting fusion genes and / or MET gene skipping mutations in solid tumors is provided for use in preparing a kit for detecting fusion genes and / or MET gene skipping mutations in solid tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0008] The present application will be further described in the form of exemplary embodiments, which will be described in detail with reference to the accompanying drawings. These embodiments are not restrictive, and include:
[0009] Figure 1 It is a flow chart of the method for detecting fusion gene and / or MET gene skipping mutation of solid tumors according to some embodiments of this specification;
[0010] Figure 2 It is a schematic diagram of the structure of the anchor joint shown in some embodiments of this specification. DETAILED DESCRIPTION
[0011] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the following is a brief introduction to the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some examples or embodiments of the present application. For ordinary technicians in this field, the present application can also be applied to other similar scenarios based on these drawings without creative work. Unless it is obvious from the language environment or otherwise explained, the same reference numerals in the figures represent the same structure or operation.
[0012] As shown in this application and claims, unless the context clearly indicates an exception, the words "a", "an", "an" and / or "the" do not refer to the singular and may also include the plural. Generally speaking, the terms "comprises" and "includes" only indicate the inclusion of the steps and elements that have been clearly identified, and these steps and elements do not constitute an exclusive list. The method or device may also include other steps or elements.
[0013] Flowcharts are used in the present application to illustrate the operations performed by the system according to the embodiments of the present application. It should be understood that the preceding or following operations are not necessarily performed accurately in order. On the contrary, the various steps may be processed in reverse order or simultaneously. At the same time, other operations may also be added to these processes, or one or more operations may be removed from these processes.
[0014] The following are definitions of some terms used in this application.
[0015] As used in this application, a "subject" (also referred to as an "individual", "object") is an object that is tested or tested. In some embodiments, the subject can be a vertebrate. In some embodiments, the vertebrate is a mammal. Mammals include, but are not limited to, primates (including humans and non-human primates) and rodents (e.g., mice and rats). In some embodiments, the mammal can be a human. In some embodiments, the "subject" is a patient with a fusion gene-positive tumor.
[0016] The term "fusion gene" refers to a new gene formed by the fusion of all or part of the sequences of two genes. It may be the result of chromosomal translocation, interstitial deletion or chromosomal inversion.
[0017] The term "primer" refers to a single-stranded polynucleotide capable of hybridizing to a nucleic acid and allowing polymerization of a complementary nucleic acid, typically by providing a free 3'-OH group.
[0018] The term "polymerase chain reaction (PCR)" is a molecular biology technique used to amplify specific DNA fragments.
[0019] The term "real-time fluorescence quantitative PCR (Quantitative Real-time PCR)" can also be referred to as qPCR or RT-PCR. qPCR is a method that uses fluorescent chemicals to detect the total amount of products after each polymerase chain reaction (PCR) cycle in a DNA amplification reaction. It can quantitatively analyze specific DNA sequences in the sample to be tested using internal or external reference methods.
[0020] The term "sample" refers to any composition containing nucleic acids isolated from a subject. The term can include purified or isolated components of cells, tissues or blood, such as DNA, RNA, proteins, cell-free fractions or cell lysates.
[0021] Gene fusion is a common feature of tumors, which can promote the occurrence and development of tumors and can be used as a target for molecular diagnosis and treatment of tumors. With the development of RNA deep sequencing technology, more and more fusion genes are gradually being discovered. At present, in the treatment of solid tumors, corresponding targeted drugs have been approved at home and abroad for driver gene fusion targets such as ALK, ROS1, RET, EGFR, FGFR1, FGFR2, FGFR3, NTRK1, NTRK2, NTRK3, NRG1, PBX1, BRAF, RAF1, PPARG, ERG, PRKACA, TFE3, and MET 14 exon skipping mutations. Therefore, by detecting targets with clinical therapeutic significance, especially providing detection results of multiple targets, more support can be provided for the subsequent treatment of patients.
[0022] At present, common fusion detection gene detection methods include: fluorescence in situ hybridization (FISH), reverse transcription polymerase chain reaction (RT-PCR), immunohistochemistry (IHC), next-generation sequencing technology (NGS), etc. The targeted capture library construction sequencing method developed based on high-throughput sequencing technology (NGS) can detect multiple target fusion genes with clear clinical significance at one time. It has advantages in detection throughput and can provide more comprehensive detection results with limited sample size, which meets the needs of clinical practice. NGS generally captures fusion genes through amplicon methods or multiple anchor amplification methods. The former requires the design of specific primers on the driver gene and partner gene of each fusion type, so it can only detect fixed fusion gene types, and cannot detect other fusions or unknown fusions with known driver genes. In addition, since the fragments it captures are of fixed length, the target fusion fragments are easily lost in fragment degradation samples such as formalin-fixed and paraffin-embedded (FFPE). The latter only designs a single-end specific primer on a known driver gene, and the other end primer is designed on a fixed sequence formed by a connector connection. Therefore, it can not only detect all types of gene fusions with the target driver gene, but also use half the number of specific primers relative to the former, greatly reducing the complexity of the multiple amplification system, and because the fragments it captures are not of fixed length, the probability of capturing the target fragment is theoretically higher than that of the amplicon method. Therefore, the NGS detection method based on multiple anchored amplification to capture fusion genes has obvious advantages. However, since multiple anchored amplification uses specific single-ended primers, it is easy to amplify and capture fragments of non-target driver genes, which reduces the capture efficiency. Therefore, the method for detecting solid tumor fusion genes in this application improves specificity by performing nested amplification on the basis of anchored amplification, that is, designing nested primers downstream of the specific single-ended primers to amplify again to improve the capture efficiency.
[0023] On the one hand, the present application provides a primer combination for detecting fusion genes and / or MET gene skipping mutations in solid tumors, the primer combination comprising: a first multiplex specific primer set, which comprises a nucleotide sequence as shown in SEQ ID NO.1-54 and a first universal primer as shown in SEQ ID NO.55, the first multiplex specific primer set is used for multiplex anchored amplification; and a second multiplex specific primer set, which comprises a nucleotide sequence as shown in SEQ ID NO.56-109 and a second universal primer as shown in SEQID NO.110, the second multiplex specific primer set is used for multiplex nested amplification.
[0024] In some embodiments, the primers for multiple anchor amplification include a first multiple specific primer set, and the first multiple specific primer set includes a nucleotide sequence as shown in SEQ ID NO.1-54. In some embodiments, the primers for PCR amplification may include at least one of the sequences with a similarity of ≥95%, ≥90%, ≥85%, ≥80%, ≥75% or ≥70% to the sequences shown in SEQ ID NO:1-54. In some embodiments, the PCR reaction system for multiple anchor amplification also includes a sequence with a similarity of ≥95%, ≥90%, ≥85%, ≥80%, ≥75% or ≥70% to the sequence shown in the first universal primer SEQ ID NO.55. Universal primers are nucleotide sequences that match the sequences on both sides of the cloning site, and the purpose is to amplify DNA fragments, mainly for sequencing. Universal primers may include nucleotide sequences that match some start and stop elements in the vector.
[0025] In some embodiments, the primers for multiple nested amplification include a second multiple specific primer set, and the second multiple specific primer set includes a nucleotide sequence as shown in SEQ ID NOs. 56 to 109. In some embodiments, the primers for PCR amplification may include at least one of a sequence having a similarity of ≥95%, ≥90%, ≥85%, ≥80%, ≥75%, or ≥70% to the sequence shown in SEQ ID NOs: 56 to 109.
[0026] In some embodiments, the PCR reaction system used in multiple nested amplification also includes a sequence with a similarity of ≥95%, ≥90%, ≥85%, ≥80%, ≥75% or ≥70% to the sequence shown in the second universal primer SEQ ID NO.110.
[0027] The primer sequences used for multiplex anchored amplification and multiplex nested amplification are shown in Table 1 ;
[0028] Table 1 Nucleotide sequences of driver genes and their primers
[0029]
[0030]
[0031]
[0032]
[0033] In some embodiments, the first multiplex specific primer set includes multiple sequences that specifically bind to the target driver gene (i.e., the driver gene shown in Table 1), and the number of primer sequences in the first multiplex specific primer set can be determined according to the number of target driver genes to be captured. The number of exemplary primer sequences in the first multiplex specific primer set can be more than 2 (e.g., 2, 5, 6, 10, 20, 50). In some embodiments, when performing multiple nested amplification, the above-mentioned second universal primer is used as an upstream primer, and the second multiplex specific primer set is used as a downstream primer. The second multiplex specific primer set is also a plurality of sequences that specifically bind to the target driver gene. The second multiplex specific primer set is characterized in that the 5'-end has a complementary sequence to the downstream sequencing primer, and the 3'-end can specifically bind to the target driver gene, and the target driver gene DNA library is obtained by multiple nested amplification.
[0034] In one aspect, the present application provides a kit for detecting solid tumor fusion genes. The kit comprises an anchor linker, a first multiplex specific primer set and a second multiplex specific primer set, wherein the first multiplex specific primer set comprises a nucleotide sequence as shown in SEQ ID NO.1-54, and the second multiplex specific primer set comprises a nucleotide sequence as shown in SEQ ID NO.56-109.
[0035] In some embodiments, the kit further comprises an anchor linker, the linker sequence is shown in Table 2 below:
[0036] Table 2 Linker sequences
[0037]
[0038] The linker sequence includes a long oligonucleotide single strand and a short oligonucleotide single strand. The long oligonucleotide single strand is a nucleotide sequence as shown in SEQ ID NO.111. The short oligonucleotide single strand is a nucleotide sequence as shown in SEQ ID NO.112. Figure 2 As shown, the short oligonucleotide single strand is annealed to form a semi-Y-shaped structure, and the long oligonucleotide single strand contains the X-connector (including sequencing connector and sample Barcode) of the Ion torrent sequencing platform. The connector has a protruding T base at the 3' end of the complementary region of the long strand. It should be noted that the Barcode sequence in some embodiments of this specification is only used as an example and is not intended to limit the scope of the present invention. The Barcode sequence may also include other sample tag sequences.
[0039] In some embodiments, RNA can be extracted from a sample of a subject, and the kit is used to reverse transcribe the RNA to obtain cDNA, and the cDNA is amplified and high-throughput sequenced by the anchoring linker, the first multiple specific primer set, and the second multiple specific primer set in the above kit. When normalized Reads ≥ 100, the fusion type is determined to be positive, and the presence of the fusion gene in the sample can be detected. For example, the detection result of the fusion type LMNA-NTRK1 is normalized Reads = 914, the detection result of the fusion type FGFR3-TACC3 is normalized Reads = 753, and the detection result of the fusion type LMNA--NTRK1 is normalized Reads = 794, then the above fusion type is determined to be positive. For another example, the detection result of the fusion type SLC1A2-MET is normalized Reads = 55, then the fusion type is determined to be negative. Through the kit of the present application, the presence of multiple fusion genes and the type of their partner genes can be accurately and quickly detected at one time.
[0040] Another aspect of the present application provides a method for detecting solid tumor fusion genes and / or MET gene skipping mutations.
[0041] Figure 1 1 is a flow chart of a method for detecting solid tumor fusion genes according to some embodiments of the present application. The method may include the following steps 101-106.
[0042] Step 101, add RNA shearing solution to the total RNA sample, shake and mix, centrifuge, run the shearing program, and obtain RNA shearing product.
[0043] Large fragments of RNA can be broken into small fragments under the action of divalent cations and high temperature. In some embodiments, RNA breaking liquid can also be used to break the RNA phosphodiester bond. In some embodiments, RNA breaking products can be obtained by adding RNA breaking liquid to the fusion gene RNA standard. The breaking procedure includes running for a first time at a first breaking temperature; running for a second time at a second breaking temperature. In some embodiments, the first breaking temperature can be between 90-100°C. Preferably, the first breaking temperature can be 94°C. The second breaking temperature can be between 5-15°C. Preferably, the second breaking temperature can be 8°C. In some embodiments, the first time of the breaking procedure is between 5-10min. Preferably, the first time is 7min. The second time of the breaking procedure is not limited. In some embodiments, the second time can be the waiting time to the next step.
[0044] In some embodiments, the step 101 may also include: extracting a total RNA sample from a sample of a subject.
[0045] In some embodiments, the subject can be a mammal, such as a human. The subject can be a tumor patient with a positive fusion gene, or a subject without gene fusion. In some embodiments, the sample to be tested refers to any composition containing nucleic acid separated from a subject. Exemplary samples may include, but are not limited to, lavage fluid (e.g., alveolar lavage fluid), oral / throat wash fluid, cerebrospinal fluid, pleural effusion, ascites, pus, sputum, saliva, urine, lymph fluid, tissue samples (e.g., fresh tissue, formalin-fixed paraffin-embedded tissue, blood samples, purified or isolated cell samples, etc., or a combination thereof) of the subject. In some embodiments, the sample may be a blood sample. The blood sample may include plasma, serum, peripheral blood, etc. In some embodiments, the sample may be a non-blood sample. Exemplary non-blood samples may include sputum, lavage fluid, pleural effusion, tissue samples, pleural effusion, ascites, cerebrospinal fluid, cell samples, etc. In some embodiments, the non-blood sample may include sputum, lavage fluid, pleural effusion, or tissue samples. Different samples may be obtained by different collection methods. For example, a non-blood sample of a subject may be collected by biopsy (e.g., puncture biopsy, liquid biopsy), surgical acquisition, and the like. For another example, a blood sample of a subject may be collected by venous blood collection, peripheral blood collection, arterial blood collection, and the like.
[0046] Step 102, add a single-strand buffer and a single-strand synthase to the RNA sheared product, shake and mix, centrifuge briefly, run a single-strand cDNA synthesis program, and reverse transcribe to obtain a single-strand cDNA product.
[0047] Reverse transcription can be a process of synthesizing complementary single-stranded DNA (cDNA) using the extracted RNA as a template by a reverse transcriptase (e.g., a single-strand synthase). In some embodiments, the extracted RNA can be reverse transcribed to obtain cDNA using a reverse transcription method known to those skilled in the art (e.g., using a reverse transcription kit). Reverse transcription of RNA into a cDNA with a more stable structure is beneficial for subsequent library construction and sequencing. The cDNA single-strand synthesis procedure includes running for a first time at a first cDNA single-strand synthesis temperature; running for a second time at a second cDNA single-strand synthesis temperature; running for a third time at a third cDNA single-strand synthesis temperature; and running for a fourth time at a fourth cDNA single-strand synthesis temperature. In some embodiments, the first cDNA single-strand synthesis temperature can be between 20-30°C. Preferably, the first cDNA single-strand synthesis temperature can be 25°C. The second cDNA single-strand synthesis temperature can be between 40-45°C. Preferably, the second cDNA single-strand synthesis temperature can be 42°C. The third cDNA single-strand synthesis temperature can be between 60-80°C. Preferably, the third cDNA single-strand synthesis temperature can be 70°C. The fourth cDNA single-strand synthesis temperature may be between 5-10°C. Preferably, the fourth cDNA single-strand synthesis temperature is 8°C. In some embodiments, the first time of the cDNA single-strand synthesis program is between 5-15min. Preferably, the first time is 10min. In some embodiments, the second time of the cDNA single-strand synthesis program is between 10-20min. Preferably, the second time is 15min. In some embodiments, the third time of the cDNA single-strand synthesis program is between 10-20min. Preferably, the first time is 15min. The fourth time of the cDNA single-strand synthesis program is not limited. In some embodiments, the fourth time may be the waiting time to the next step.
[0048] Step 103, add the second-strand buffer and the second-strand synthesis end repair and A addition reaction solution to the cDNA first-strand product, oscillate to mix, centrifuge, run the cDNA second-strand synthesis, end repair and A addition program, reverse transcribe the cDNA second strand and simultaneously end repair and A addition to obtain a cDNA second-strand product.
[0049] The cDNA double-strand synthesis program includes running a first time at a first cDNA double-strand synthesis temperature; running a second time at a second cDNA double-strand synthesis temperature; and running a third time at a third cDNA double-strand synthesis temperature. In some embodiments, the first cDNA double-strand synthesis temperature may be between 10-20°C. Preferably, the first cDNA double-strand synthesis temperature may be 16°C. The second cDNA double-strand synthesis temperature may be between 65-75°C. Preferably, the second cDNA double-strand synthesis temperature may be 72°C. The third cDNA double-strand synthesis temperature may be between 5-10°C. Preferably, the third cDNA double-strand synthesis temperature may be 8°C. In some embodiments, the first time of the cDNA double-strand synthesis program is between 25-35min. Preferably, the first time is 30min. In some embodiments, the second time of the cDNA double-strand synthesis program is between 10-20min. Preferably, the second time is 15min. The third time of the cDNA double-strand synthesis program is not limited. In some embodiments, the third time may be the waiting time to the next step.
[0050] Step 104, connecting the double-stranded cDNA product to the anchoring adapter and purifying it to obtain a purified pre-library connected to the anchoring adapter.
[0051] In some embodiments, the adapter connection system is used to add adapters to the treated cDNA so that the cDNA is connected to the adapter. For different sequencing platforms, adapters of different platforms can be added. The adapter is a specially designed deoxyribonucleic acid sequence. After being fixed at both ends of the DNA fragment by connection (for example, by adapter ligase) and other methods, it can be identified during sequencing and used as the starting point of sequencing for the instrument to read the sequence information thereafter. Due to the different library structures of different platforms, the adapter structures used are also different. Using different adapters in this step can meet the needs of different sequencing platforms for libraries. For example, for the Illumina sequencing platform, a Y-type adapter can be used. The adapter can include a universal adapter and an indexed adapter. The universal adapter is related to the sequencing platform. The same sequencing platform has the same universal adapter. Index (or barcode) is an oligonucleotide chain composed of several bases, which is used to distinguish different samples during sequencing. In some embodiments, in some embodiments, adapter ligase and adapter connection buffer can be used to connect DNA and cDNA to the adapter. In some embodiments, the adapter ligase can be T4 DNA ligase.
[0052] The joint connection procedure includes running at a first joint connection temperature for a first time; running at a second joint connection temperature for a second time. In some embodiments, the first joint connection temperature may be between 10-30°C. Preferably, the first joint connection temperature may be 20°C. In some embodiments, the first time of the joint connection procedure is between 10-20min. Preferably, the first time is 15min. The second time of the joint connection procedure is not limited. In some embodiments, the second time may be a waiting time until the next step.
[0053] Step 105, connect the double-stranded cDNA product to the anchor linker and purify it to obtain a purified pre-library connected to the anchor linker; add the pre-library, the first multiple specific primer set as shown in SEQ ID NO.1-54 and the first universal primer as shown in SEQ ID NO.55 to the PCR reaction system, perform PCR amplification, obtain multiple anchor amplification products and purify them.
[0054] Step 106, adding the purified multiple anchor amplification products, the second multiple specific primer set as shown in SEQ ID NO.56-109 and the second universal primer as shown in SEQ ID NO.110 to the PCR reaction system, performing PCR amplification to obtain multiple nested amplification products and purifying them to obtain a DNA library.
[0055] In some embodiments, the method for detecting solid tumor fusion genes and / or MET gene skipping mutations further includes a library quality inspection step, for example, using a Qubit fluorometer to detect the library concentration of the DNA library.
[0056] In some embodiments, the method for detecting solid tumor fusion genes and / or MET gene skipping mutations further comprises a high-throughput sequencing step, for example, performing high-throughput sequencing on the DNA library using an Ion Proton or Ion PGM sequencing platform.
[0057] In some embodiments, part or all of the above steps can be performed by a computing device. For example, the data analysis process after sequencing is completed by a PCR instrument. The computing device may include a processing device (or processor), a memory, an input / output interface, and a communication port. The processing device may execute computing instructions (program code) and perform the steps described in this application (e.g., library quality inspection steps and high-throughput sequencing steps). The computing instructions may include programs, objects, components, data structures, processes, modules, and functions (functions refer to specific functions described in this application). In some embodiments, the processing device may include a microcontroller, a microprocessor, a reduced instruction set computer (RISC), an application-specific integrated circuit (ASIC), an application-specific instruction set processor (ASIP), a central processing unit (CPU), a graphics processing unit (GPU), a physical processing unit (PPU), a microcontroller unit, a digital signal processor (DSP), a field programmable gate array (FPGA), an advanced RISC machine (ARM), a programmable logic device, and any circuit and processor capable of performing one or more functions, or any combination thereof.
[0058] The method for detecting solid tumor fusion genes and / or MET gene skipping mutations provided by the present application can detect all types of fusions with selected driver genes without limiting the partner genes, which can make up for the defect that the previous amplicon NGS detection method cannot detect fusions with partner genes that are not in the selected range. Therefore, compared with the detection product of amplicon NGS that selects fixed partner genes, the solid tumor fusion gene detection method has a wider range of fusion genes and can detect rare fusion types.
[0059] It should be noted that the above Figure 1 The description of the method steps is only for example and explanation, and does not limit the scope of application of the present application. For those skilled in the art, various modifications and changes can be made to the steps under the guidance of the present application. However, these modifications and changes are still within the scope of the present application.
[0060] Another aspect of the present specification provides a primer combination for detecting fusion genes and / or MET gene skipping mutations in solid tumors in the preparation of a kit for detecting fusion genes and / or MET gene skipping mutations in solid tumors. In some embodiments, the driver gene includes one or more of ALK, ROS1, RET, EGFR, FGFR1, FGFR 2, FGFR 3, NTRK1, NTRK2, NTRK3, NRG1, PBX1, BRAF, RAF1, PPARG, ERG, PRKACA, TFE3, and the fusion gene includes all fusion types for the driver gene; the MET gene includes at least one of MET14 and MET15. Exemplary driver genes and their fusion types are shown in Table 3:
[0061] Table 3 Driver genes and their partner genes
[0062]
[0063] Example
[0064] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are purchased from conventional biochemical reagent companies unless otherwise specified. The quantitative tests in the following examples are repeated multiple times, and the results are averaged.
[0065] Example 1. Kit for detecting solid tumor fusion genes
[0066] 1. Experimental process
[0067] 1.1 Preparation of negative sample solution
[0068] The total RNA of the sample to be tested is extracted using an RNA extraction kit (DP419) from Beijing Tiangen Biochemical Technology Co., Ltd. In some embodiments, the sample to be tested is a negative cell line sample. The total RNA concentration is determined using Qubit, and then the total RNA is diluted to a final concentration of 50 ng / μL to obtain a negative sample solution.
[0069] 1.2 Preparation of fusion gene RNA standards
[0070] Six fusion gene RNA standards, including LMNA (2)-NTRK1 (11), FGFR3-TACC, ETV6 (4)-NTRK3 (14), EZR (10)-ROS1 (34), EML4 (20)-ALK (20), and CCDC6 (1)-RET (12), were selected. Each fusion gene RNA standard was diluted to 600 copies / μL, and then the six fusion gene RNA standards were mixed to obtain a mixed RNA standard solution containing 100 copies / μL of the above six fusion genes. The 50 ng / μL negative sample solution prepared in 1.1 was mixed with the 100 copies / μL RNA standard mixed solution in equal proportions to obtain a fusion gene RNA standard with a negative sample concentration of 25 ng / μL and 50 copies / μL of the above six fusion genes.
[0071] 1.3 Cutting off total RNA
[0072] Take out the fragmentation solution, thaw, mix, and centrifuge, prepare the system shown in Table 1 on an ice box, oscillate and mix the system, centrifuge, and run the fragmentation program shown in Table 3 to obtain RNA fragmentation products.
[0073] Table 4 Interruption program parameters and system components and contents
[0074]
[0075] 1.4 Reverse transcription of cDNA strand
[0076] Take out the first-strand buffer and the first-strand synthase, thaw, mix, and centrifuge, and prepare the reaction system shown in Table 2 on an ice box. Run the cDNA first-strand synthesis program shown in Table 5, and reverse transcribe to obtain the cDNA first-strand product.
[0077] Table 5 cDNA one-strand synthesis procedure and system components and contents
[0078]
[0079]
[0080] 1.5 Reverse transcription of cDNA second strand and simultaneous end repair and A addition
[0081] Take out the second-strand buffer and the second-strand synthesis end-repair plus A reaction solution, thaw, mix, and centrifuge, and prepare the reaction system shown in Table 3 on an ice box. Add the second-strand buffer and the second-strand synthesis end-repair plus A reaction solution to the cDNA first-strand product, oscillate and mix, centrifuge, and run the cDNA second-strand synthesis, end-repair plus A program shown in Table 6, reverse transcribe the cDNA second strand, and simultaneously end-repair plus A to obtain the cDNA second-strand product.
[0082] Table 6 cDNA second-strand synthesis procedures and system components and contents
[0083]
[0084] 1.6 Connector connection
[0085] Take out the ligation reaction solution, T4 ligase, and anchor adapter, thaw, mix, and centrifuge, and prepare the reaction system shown in Table 7 on an ice box. Connect the double-stranded cDNA product to the anchor adapter and purify it with magnetic beads to obtain a purified pre-library connected to the anchor adapter.
[0086] Table 7 Joint connection procedure parameters and system components and contents
[0087]
[0088]
[0089] 1.7 Multiple anchor amplification
[0090] The first multiplex specific primer set and amplification reaction solution were taken out, mixed, and centrifuged briefly to prepare a reaction system as shown in Table 8 on an ice box. The pre-library connected to the anchor adapter purified in 1.6 and the first multiplex specific primer set were added to the PCR reaction system for PCR amplification to obtain multiple anchor amplification products, which were purified using magnetic beads.
[0091] Table 8 Multiple anchor amplification program parameters and system components and contents
[0092]
[0093] 1.8 Multiplex nested amplification
[0094] Take out the multiple specific primers 2 and the amplification reaction solution, mix them evenly, centrifuge them instantly, and prepare the reaction system shown in Table 9 on an ice box. Add the purified multiple anchor amplification products and the second multiple specific primer set to the PCR reaction system, perform PCR amplification, obtain multiple nested amplification products, and purify the multiple nested amplification products using magnetic beads to obtain a DNA library targeting the fusion gene.
[0095] Table 9 Multiple nested amplification program parameters and system components and contents
[0096]
[0097]
[0098] 1.9 Library quality control
[0099] The library concentration of the DNA library is detected by using a Qubit fluorometer;
[0100] 2.0 High-throughput Sequencing
[0101] The DNA library was sequenced using the Ion Proton or Ion PGM sequencing platform.
[0102] 2. Detection Results
[0103] Table 10 Detection results of six fusion gene RNA standards
[0104]
[0105]
[0106]
[0107]
[0108]
[0109]
[0110]
[0111] Result analysis: When normalizedReads≥100, the fusion type was determined to be positive. This kit can be used to repeatedly detect 100 copies of LMNA(2)-NTRK1(11), FGFR3-TACC, ETV6(4)-NTRK3(14), EZR(10)-ROS1(34), EML4(20)-ALK(20), CCDC6(1)-RET(12) in 50ng RNA. The kit of the embodiment of this specification can perform multi-gene joint mutation detection based on a high-throughput sequencing platform, and can use limited samples to identify as many gene fusions related to solid tumors as possible. It has high detection efficiency, can reduce detection costs, and has important clinical significance in the detection of solid tumor fusion genes.
[0112] Example 2: Comparison of clinical sample testing
[0113] FFPE RNA samples from 20 lung cancer patients were tested. According to previous amplicon NGS test results, 10 samples tested positive and 10 samples tested negative (see Table 11).
[0114] Table 11 Previous amplicon NGS test results
[0115]
[0116] 1. Experimental process
[0117] 1. Sample Preparation
[0118] The above 20 FFPE RNA samples were dispatched from the sample center, and the Qubit nucleic acid concentration information was queried from the system.
[0119] 2.FFPE RNA Shearing
[0120] (1) Take out the 2× disruption solution, thaw, mix, and centrifuge. Prepare the reaction system shown in Table 12 on an ice box to ensure that the input amount of each sample is 50 ng. Vortex to mix, centrifuge, and run the disruption program.
[0121] Table 12 System components and contents in the interruption procedure
[0122] Components Volume (μL) Breaking fluid 8.5 FFPE RNA samples 50ng water Refill to 17 μL Total volume 17
[0123] 3. Subsequent experimental operation steps: reverse transcription of one cDNA strand, reverse transcription of two cDNA strands and simultaneous end repair and A addition, anchor adapter ligation, multiple anchor amplification, multiple nested amplification operation, library quality inspection and high-throughput sequencing are the same as in Example 1.
[0124] 4. Sequencing results
[0125] The sequencing results are shown in Table 13.
[0126] Table 13 Sequencing results of FFPE RNA samples from 20 lung cancer patients
[0127]
[0128]
[0129] 5. Results Analysis
[0130] B01 to B10, a total of 10 samples that were previously positive for amplicon-NGS testing, the results of this method are completely consistent with the previous results (10 / 10, 100%). B11 to B20, a total of 10 samples that were previously negative for amplicon-NGS testing, the results of this method are 8 negative (8 / 10, 80%), and 2 samples detected fusion mutations, of which B14 detected HIP1-ALK fusion and B20 detected CLTC-ALK fusion. The previous amplicon NGS detection method can detect fusions between the selected driver gene and the selected partner gene, but cannot detect fusions with partner genes that are not in the selected range. Partner genes such as HIP1 and CLTC are not in the selected range, so they cannot be detected. However, this kit can detect all fusion types with the selected driver gene, without limiting the partner gene. Therefore, compared with the detection products that select fixed partner genes for amplicon NGS, this kit has a wider range of fusion detection and can detect rare fusion types.
[0131] The primer combination, kit and method for detecting fusion gene and / or MET gene skipping mutation in solid tumor disclosed in the embodiments of this specification may bring beneficial effects including but not limited to: (1) based on ALK, ROS1, RET, EGFR, FGFR1, FGFR 2, FGFR 3. The first multiplex specific primer set and the second multiplex specific primer set designed for NTRK1, NTRK2, NTRK3, NRG1, PBX1, BRAF, RAF1, PPARG, ERG, PRKACA, and TFE3 driver genes can effectively capture the target driver gene region with strong specificity. When the partner gene is unknown, the above fusion genes and their partner genes can be accurately and sensitively detected; (2) The targeted capture library construction sequencing method developed based on high-throughput sequencing technology (NGS) can simultaneously detect multiple target fusion genes with clear clinical significance at one time, has advantages in detection throughput, can provide more comprehensive detection results with limited sample size, reduce detection costs, and meet the needs of clinical practice; (3) On the basis of anchored amplification, the specificity is improved by performing nested amplification, that is, a nested primer is designed downstream of the specific single-end primer for further amplification to improve the capture efficiency.
[0132] Those skilled in the art should understand that the above embodiments are only for illustrating the present invention and do not limit the present invention. Any modification, equivalent substitution and change made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A kit for detecting fusion genes and MET gene skipping mutations in solid tumors, characterized in that: The kit comprises: A first multiplex specific primer set, comprising the nucleotide sequences shown in SEQ ID NOs. 1-54, wherein the first multiplex specific primer set is used for multiplex anchor amplification; a second multiplex specific primer set, comprising nucleotide sequences as shown in SEQ ID NOs. 56-109, wherein the second multiplex specific primer set is used for multiplex nested amplification; A first universal primer for multiple anchored amplification as shown in SEQ ID NO.55 and a second universal primer for multiple nested amplification as shown in SEQ ID NO.110; and An anchoring linker, wherein the anchoring linker is formed by annealing the nucleotide sequences shown in SEQ ID NO.111 and SEQ ID NO.112 to form a half-Y-shaped structure when constructing the pre-library, wherein The anchoring linker contains a sample Barcode and has a protruding T base at the 3' end of the complementary region of the nucleotide sequence shown by SEQ ID NO.
111.
2. The kit according to claim 1, characterized in that The kit also includes one or more of the following reagents: RNA extraction reagent, RNA shearing solution, reverse transcription cDNA first-strand reagent, reverse transcription cDNA second-strand and end repair plus A reagent, adapter connection reagent, multiple anchor amplification reaction reagent, multiple nested amplification reaction reagent.
3. The kit according to claim 2, characterized in that The reverse transcription cDNA one-strand reagent includes a one-strand buffer and a one-strand synthase; The reverse transcription cDNA second strand and end repair plus A reagents include a second strand buffer and a second strand synthesis end repair plus A reaction solution; The linker ligation reagent includes a ligation reaction solution and T4 ligase.
